RNS Number : 5123A
OptiBiotix Health PLC
29 May 2019

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Director's Dealing

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification on 29 May 2019 that Frédéric Narbel, a recently appointed Director of the Company, acquired 12,000 ordinary shares in the Company on 29 May 2019, representing 0.01% of the Company's issued share capital, at a price of 89 pence per share.

Prior to this announcement, Mr Narbel did not hold any ordinary shares in the Company.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive *Contact via Walbrook below*

Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner

finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty five international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

<table>
<tr><td colspan="3">Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</td></tr>
<tr><td>1</td><td colspan="2">Details of the person discharging managerial responsibilities/person closely associated</td></tr>
<tr><td>a.</td><td>Name</td><td>Frédéric André Narbel</td></tr>
<tr><td>2</td><td>Reason for notification</td><td></td></tr>
<tr><td>a.</td><td>Position/Status</td><td>Director of the Company</td></tr>
<tr><td>b.</td><td>Initial notification/

Amendment</td><td>Initial Notification</td></tr>
<tr><td>3</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a.</td><td>Name</td><td>OptiBiotix Health Plc</td></tr>
<tr><td>b.</td><td>LEI</td><td>213800UKYQFT941QHS14</td></tr>
<tr><td>4</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the financial instrument, type of instrument

Identification Code</td><td>12,000 ordinary shares of 2p each

ISIN: GB00BP0RTP38</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Purchase of 12,000 ordinary shares in the Company</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><td>Price(s) per share</td><td>Volume(s)</td></tr></table></td></tr>
</table>

		89p | 12,000
e.	Date of the transaction	29 May 2019
f.	Place of the transaction	London Stock Exchange, AIM

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHZKLFLKEFFBBZ